期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肺腺癌吉非替尼获得性耐药相关microRNAs的筛选鉴定 被引量：7

Screening and Identification of MicroRNAs Related to Acquired Gefitinib-resistance in Lung Adenocarcinoma Cell Lines
在线阅读 下载PDF
导出
摘要 背景与目的肺腺癌吉非替尼获得性耐药严重影响了肺癌的治疗效果,microRNA在肺腺癌吉非替尼获得性耐药中的作用及其机制尚不清楚。本研究筛选与肺腺癌获得性吉非替尼耐药相关的microRNAs。方法以吉非替尼敏感肺癌细胞PC9与吉非替尼耐药肺癌细胞PC9/AB11为细胞模型,观察二者的形态学差异,流式细胞仪检测二者的细胞周期,计算它们的倍增时间,MTT法检测吉非替尼对两种细胞的IC50,应用microRNA芯片检测和筛选与吉非替尼耐药相关的microRNAs,并进行real-timePCR验证。结果 PC9细胞与PC9/AB11细胞形态差异明显,在细胞周期、倍增时间和吉非替尼对其的IC50上均具有统计学差异。microRNA芯片结果显示,与PC9相比,耐药肺癌细胞株PC9/AB11中有4个microRNAs表达水平明显上调,有9个microRNAs表达水平明显下调。经real-timePCR验证,microRNA-138在PC9/AB11中表达明显下调,与芯片结果一致。结论 PC9和PC9/AB11细胞株microRNA表达谱存在明显差异,初步筛选到了13个与肺腺癌吉非替尼耐药密切相关的microRNAs,为进一步深入研究microRNA在肺腺癌吉非替尼获得性耐药中的作用及其分子机制提供了实验依据和理论基础。 Background and objective Acquired gefitinib-resistance was closely related to inefficiency of EGFR-TKI treatment in lung adenocarcinoma. However, it was not clear that how microRNAs influenced the acquired gefitinib-resistance in lung adenocarcinoma. The aim of this study is to screen and identify the microRNAs correlated with the acquired gefitinib -resistance in lung adenocarcinoma. Methods Morphological difference was observed in gefitinib-sensitive lung adenocarcinoma cell line PC9 cell line and gefitinib-resistance lung adenocarcinoma cell line PC9/AB11 cell line derived from PC9 cell line. Cell cycles and doubling time were detected by flow cytometry, IC50 of gefitinib was evaluated by MTT assay. The differential microRNAs related to acquired gefitinib-resistance were screened and identified by microRNA array and real-time PCR. Results There were obvious morphological differences between PC9 and PC9/AB11 cells. The doubling time, distribu-tion of cell cycle, and the IC50 between PC9 and PC9/AB11 were significantly different. In microarray analysis, compared with PC9 cell line, 4 up-regulated microRNAs were found in PC9/AB11 cells, 9 down-regulated microRNAs were found in PC9/AB11 cells. Real-time PCR revealed that miR-138 was significantly down-regulated in PC9/AB11 cells, accord with the micro-array. Conclusion MicroRNAs are involved in acquired Gefitinib-resistance of lung adenocarcinoma. Our data presented here to provide an experimental basis and theory thereunder for further study of effect and molecule mechanism underlying the acquired gefitinib-resistance of lung cancer.
作者 秦学博 刘彬 李洋 尤嘉琮 周清华
机构地区 天津医科大学总医院天津市肺癌研究所
出处 《中国肺癌杂志》 CAS 2011年第6期478-483,共6页 Chinese Journal of Lung Cancer
基金 国家自然科学基金重点项目(No.30430300),国家自然科学基金项目(No.81000950) 国家“863”重大项目(No.2006AAO2A401) 国家“973”重大项目(No.2010CB529405) 天津市科技支撑计划重点项目(No.06YFSZSF05300) 天津市创新体系建设项目(No.07SYSYSF05000,No.07SYSYJC27900)资助 中瑞合作重大项目(No.09ZCZDSF04100)资助~~
关键词 肺肿瘤 MICRORNA 吉非替尼 获得性耐药 Lung neoplasms microRNAs Gefitinib Aquired-resistance
分类号 R734.2 [医药卫生—肿瘤]
作者简介 通讯作者：尤嘉琮，E-mail：youjiacong@yahoo.cn 通讯作者：周清华，E-mail：zhouqh1016@yahoo．com．cn；
  • 相关文献

参考文献40

  • 1Jemal A, Tiwari RC, Murray T, et al. Cancer statistics. CA Cancer J Clin,2004, 54(1): 8-29.
  • 2Rusch V, Baselga J, Cordon-Cardo C, et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-smaU cell lung cancers and adjacent benign lung. Cancer Res, 1993, 53(10 Suppl): 2379-2385.
  • 3Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res, 2001, 7(10): 2958-2970.
  • 4PaezJG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004, 304(5676): 1497-1500.
  • 5刘伦旭,李为民,李潞,李娟,周清华.吉非替尼(Iressa)治疗复发性非小细胞肺癌[J].中国肺癌杂志,2004,7(4):321-324. 被引量：14
  • 6王燕,张湘茹,王彬,王子平,储大同,孙燕.吉非替尼治疗69例老年肺腺癌的临床分析[J].中国肺癌杂志,2008,11(1):137-141. 被引量：10
  • 7Morgillo F, Kim WY, Kim ES, et al. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res, 2007, 13 (9): 2795-2803.
  • 8Riely G J, politi KA, Miller VA, et al. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res, 2006, 12(24): 7232-7241.
  • 9Tracy S, Mukohara T, Hansen M, et al. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res, 2004, 64(20): 7241-7244.
  • 10Hoshi S, Yamaguchi T, Kono C, et al. Recurrence of non-small cell lung cancer after successful treatment with gefitinib-report of three cases. Gan To Kagaku Ryoho, 2004, 31(8): 1209-1213.

二级参考文献28

  • 1Raben D, Helfrich BA, Chan D, et al. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol, 2002, 2
  • 2Bianco C, Tortora G, Bianco R, et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res,2002,8(10) :3250-3258.
  • 3Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res,2001,7(5) : 1459-1465.
  • 4Herbst RS, Maddox AM, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase Ⅰ trial. J
  • 5Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase,in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA,2003,290(16): 2149-2158.
  • 6Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res,2000,6(6) : 2166-2174.
  • 7Raden D, Helfrich B, Chan D, et al. C225 anti-EGFR antibody potentiates radiation (RT) and chemotherapy (CT) cytotoxicity in human non-small cell lung (NSCLC) cells in vitro and in vivo.Proc Am Soc Clin Oncol,2001,20(2): 257a.
  • 8Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non small-cell lung cancer. J Clin Oncol, 2003,21(12): 2237-2246. Epub 2003 May 14.
  • 9Bailey LR, Kris M, Wolf M, et al. Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib (‘ Iressa ', ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer: IDEAL 1 and 2. Proc Am
  • 10Muthuswamy SK, Gilman M, Brugge JS. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Bio1,1999,19(10): 6845-6857.

共引文献22

同被引文献64

  • 1Grishok A, Pasquinelli AE, C onte D, et al. Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C-elegans developmental timing. Cell, 2001, 106(1): 23-34.
  • 2Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and rniRNAs exhibit strand bias. Cell, 2003, 115(2): 209-216.
  • 3Lee Y, Ahn C, Han JJ, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature, 2003, 425(6956): 415-419.
  • 4Lee RC, Feinbaum RL, Ambros V. The C. Elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 1993, 75(5): 843-854.
  • 5Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA, 2002, 99(24): 15524-15529.
  • 6Chen CZ. MicroRNAs as oncogenes and tumor suppressors. N EnglJ Med, 2005, 353(17): 1768-1771.
  • 7Croce CM. Causes and consequences of microRNA dysregnlation in cancer. Nature Reviews Genetics, 2009, 10(10): 704-714.
  • 8Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA, 2006, 103(7): 2257-2261.
  • 9Hipfner DR, Weigmann K, Cohen SM. The bantam gene regulates Drosophila growth. Genetics, 2002, 161(4): 1527-1537.
  • 10Cheng AM, Byrom MW, Shelton J, et al. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res, 2005, 33(4): 1290-1297.

引证文献7

二级引证文献30

中国肺癌杂志
2011年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
关于我们 | 版权声明 | 联系我们 | 帮助中心| 意见反馈
主办单位：上海市教育委员会
技术支持：重庆维普资讯有限公司
渝公网安备 50019002500403号
使用帮助 返回顶部